Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02675140
Other study ID # ChengduWCCH
Secondary ID
Status Completed
Phase Phase 4
First received August 28, 2015
Last updated February 4, 2016
Start date March 2012
Est. completion date March 2015

Study information

Verified date February 2016
Source Chengdu Maternal and Children's Health Care Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

The present study is intended to supplement the preschool anemic children with vitamin A capsule and de-hookworm administration in poverty Sichuan province. We eventually expect our study can provide a cost-effective, safe and more beneficial public health strategy to manage the anemia status of preschool children in poverty area.


Description:

Subjects and ethical approval This randomized, control and double-blinded cohort study was performed in Dayi, Pixian and Meishan country, Sichuan Province, western China, which are suburbs of Chengdu city with a low class of socioeconomic status, from March 2012 to September 2014 and approximately about 216 anemic preschool children aged 3-6 years were randomly recruited from nine kindergartens of the three countries for the study during intervention period. The eligibility criteria for participation were as follows: 1) apparent health; 2) Hb concentration <110 g/l but not <80 g/l; 3) C-reaction protein (CRP) <10 mg/L; 4) parental or guardian approval of participation in all aspects of the study; and 5) parental/guardian agreement to avoid the additional use of vitamin and mineral supplements and de-hookworm administration during the trial. Children with Hb<80 g/l and /or CRP >10 mg/l were sent to hospital with special treatment.

We conducted a census in each regional kindergarten to determine which households included an eligibility preschool children. Then field health workers conducted a family survey to determine which children was included. Eligible families were visited by a field worker who explained the protocol, answered questions, and obtained written informed consent from parents/guardians. The enrollment and research plan were reviewed and approved by the institutional ethics committee of the Chengdu Women's and Children's Central Hospital of Chongqing Medical University in Sichuan province, China. The present study complied with the code of ethics of the World Medical Association (Declaration of Helsinki).

The primary objective for the present study was to measure the change in serum Hb before and after intervention. A sample size of about 60 anemic preschool children per group was required to detect an absolute difference of 10 g/L of Hb concentration among three intervention groups after supplementation with 95% power and α= 0.05 for a two-sided two-sample t-test. To allow for 20% rate of dropout over the duration of the study, we initially planed to recruit about 72 anemic children per group (totally 216). We estimated that the prevalence of anemia of preschool children in locality was about 16%[17], eventually about 1350 children were recruited into an initial Hb screening study before intervention and about 450 for each group.

Intervention All eligible anemic children were randomly divided into three groups: Group 1 was received no intervention as control group; Group 2 was received 400 mg single-dose albendazole administration and Group 3 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially. For ethical reason, all of the children in control group were given a single-dose albendazole at the end of study. Immediately after recruitment, children in one class were assigned a study number that had been previously randomly assigned to the intervention or control group with fixed, equal allocation to each group prepared by a third party. The RAND function of Excel (Microsoft, Redmond, WA, USA) was used to generate computer randomly permutated codes. The physicians, nurses, field health workers, parents, children and laboratory personnel were blinded to the treatment assignment of each child throughout the study period. The data manager, statistician, and all investigators remained blinded to group assignments until the end of data analysis. The total duration of intervention and evaluation were six months. Vitamin A capsule and albendazole tablet were provided by Sichuan Pearl Pharmaceutical Co., Ltd.

Compliance Compliance of albendazole tablet and vitamin A capsule were monitored using recording tables, in which teachers recorded whether the child consumed "all" or "none" of the albendazole tablet and vitamin A capsule. To avoid exchange of albendazole tablet and vitamin A capsule by classmates, the three groups were physically separated by being moved to opposite corners of the classroom. Distribution and consumption of the albendazole tablet and vitamin A capsule took place under close supervision; children in group 2 and group 3 were not allowed to leave the classroom or return to their original seats before they had finished eating their albendazole tablet and vitamin A capsule. The distribution of tablets was performed by nursery managers, but not health care workers and nursery teachers. Information on the acceptability of the albendazole tablet and vitamin A capsule was obtained by a short questionnaire after administered.

Questionnaire interview A 30-minute questionnaire was conducted by a trained interviewer after recruitment. The questionnaire included questions on demographic information (children's age, sex), educational levels of main caregivers ( who were at least responsible for the half of care time of children), monthly family income, use of vitamin/mineral supplement before trial and food frequency recall (the frequency of deep-colored vegetables and milk, liver and egg).

Anthropometric measurements Anthropometric examinations were conducted by the same trained anthropometric nurse at baseline and follow-up (6-mo) time points using standardized techniques to eliminate intra-examiner error. Duplicate measurements were performed for all children. The inter-examiner coefficient of variation of weight and height for each examiner in each group was less than 5%. Weight was recorded using a weighing scale (100Med, Beijing, China) to the nearest 100 g with subjects in minimal clothing and bare feet. Similarly, height was measured in the standard position by a height scale (Haode, Guangzhou, China) to the nearest 0.1 cm. By using reference data from World Health Organization (WHO; 2005), the Z-scores were calculated for height for age (HAZ), weight for height (WHZ), and weight for age (WAZ). All indices were computed using Anthro (2005) for the personal computer, as recommended by the WHO (http://www.who.int/childgrowth/software/en/).

Blood sample collection and biochemical assessment At the beginning and at 3 and 6 month after intervention, three blood samples (about 1 mL) were collected by venipuncture of an antecubital vein from each subject before breakfast in hospital. A quarter of a milliliter was drawn into a container containing heparin to measure Hb by the hemoglobincyanide method (Maker, Chengdu, China). The interassay variation was lower than 5% and the intra-assay variation was lower than 10%. The blood samples were immediately stored at 4° C to prevent micro-hemolysis and were separated within 5 h. The remaining blood was centrifuged at 3000g for 5 min at room temperature. The centrifuged serum samples were divided into aliquots and immediately transported to the laboratory and stored at -20°C. The concentrations of serum ferritin (SF) were measured using a commercial enzyme-linked immunosorbent assay (ELISA) (Sunbiote, Shanghai, China). Serum soluble transferrin receptor (sTfR) was measured by microparticle-enhanced immunoassay (Sunbiote, Shanghai, China). CRP was measured by particle-enhanced immunoturbidimetry (Sunbiote, Shanghai, China). Serum retinol concentration was determined by using high-performance liquid chromatography. Serum retinol was measured by experienced examiners in the Pediatric Laboratory of Chongqing Medical University and the other biochemical indices in Clinical Laboratory Center of Chengdu Women & Children's Central Hospital.


Recruitment information / eligibility

Status Completed
Enrollment 209
Est. completion date March 2015
Est. primary completion date September 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 3 Years to 6 Years
Eligibility Inclusion Criteria:

1. Apparent health

2. Hb concentration <110 g/l but not <80 g/l

3. C-reaction protein (CRP) <10 mg/L

4. Parental or guardian approval of participation in all aspects of the study

5. Parental/guardian agreement to avoid the additional use of vitamin and mineral supplements and de-hookworm administration during the trial.-

Exclusion Criteria:

1) Children with Hb<80 g/l and /or CRP >10 mg/l were sent to hospital with special treatment

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
ZENTEL
Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
ZENTEL and Vitamin A Soft Capsules
Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chengdu Maternal and Children's Health Care Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Hemoglobin concentration six month No
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A